{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T17:41:49Z","timestamp":1748367709316,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T00:00:00Z","timestamp":1546473600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s11523-018-0613-y","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T16:27:57Z","timestamp":1546532877000},"page":"33-38","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7357-0392","authenticated-orcid":false,"given":"Ilya","family":"Tsimafeyeu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Borisov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Abdelgafur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Leonenkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Novikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Guseva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Demchenkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadezhda","family":"Mikhailova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey","family":"Semenov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zakhar","family":"Yurmazov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Sivunova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madina","family":"Ramazanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey","family":"Gamayunov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry","family":"Kosov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennady","family":"Bratslavsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,3]]},"reference":[{"key":"613_CR1","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/j.1464-410X.2010.09990.x","volume":"108","author":"D Josephs","year":"2011","unstructured":"Josephs D, Hutson TE, Cowey CL, et al. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int. 2011;108:1279\u201383.","journal-title":"BJU Int"},{"key":"613_CR2","unstructured":"Kaprin AD, Starinskiy VV, Petrova GV. Malignant tumors in Russia in 2016 (morbidity and mortality). Moscow, 2018, 250 pp. ISBN 978-5-85502-234-6."},{"issue":"6","key":"613_CR3","doi-asserted-by":"publisher","first-page":"e1069","DOI":"10.1016\/j.clgc.2017.07.017","volume":"15","author":"I Tsimafeyeu","year":"2017","unstructured":"Tsimafeyeu I, Zolotareva T, Varlamov S, et al. Five-year survival of patients with metastatic renal cell carcinoma in the Russian Federation: results from the RENSUR5 registry. Clin Genitourin Cancer. 2017;15(6):e1069\u201372.","journal-title":"Clin Genitourin Cancer"},{"issue":"14","key":"613_CR4","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277\u201390.","journal-title":"N Engl J Med"},{"issue":"6","key":"613_CR5","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.eururo.2017.02.010","volume":"72","author":"B Escudier","year":"2017","unstructured":"Escudier B, Sharma P, McDermott DF, et al. CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol. 2017;72(6):962\u201371.","journal-title":"Eur Urol"},{"key":"613_CR6","doi-asserted-by":"publisher","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","volume":"14","author":"DD Hu-Lowe","year":"2008","unstructured":"Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008;14:7272\u201383.","journal-title":"Clin Cancer Res"},{"key":"613_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.clgc.2016.05.008","volume":"15","author":"TE Hutson","year":"2017","unstructured":"Hutson TE, Al-Shukri S, Stus VP, et al. Axitinib versus sorafenib in first-line metastatic renal cell carcinoma: overall survival from a randomized phase III trial. Clin Genitourin Cancer. 2017;15:72\u20136.","journal-title":"Clin Genitourin Cancer"},{"key":"613_CR8","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S1470-2045(13)70465-0","volume":"14","author":"TE Hutson","year":"2013","unstructured":"Hutson TE, Lesovoy V, Al-Shukri S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 2013;14:1287\u201394.","journal-title":"Lancet Oncol"},{"issue":"9807","key":"613_CR9","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2011","unstructured":"Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931\u20139.","journal-title":"Lancet"},{"key":"613_CR10","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794\u20139.","journal-title":"J Clin Oncol"},{"key":"613_CR11","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Kidney Cancer, version 3.2018."},{"issue":"7","key":"613_CR12","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","volume":"17","author":"TK Choueiri","year":"2016","unstructured":"Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917\u201327.","journal-title":"Lancet Oncol"},{"issue":"15","key":"613_CR13","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","volume":"16","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473\u201382.","journal-title":"Lancet Oncol"},{"key":"613_CR14","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1093\/annonc\/mdu552","volume":"26","author":"R Elaidi","year":"2015","unstructured":"Elaidi R, Harbaoui A, Beuselinck B, et al. Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma. Ann Oncol. 2015;26:378\u201385.","journal-title":"Ann Oncol"},{"issue":"6","key":"613_CR15","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.eururo.2016.09.047","volume":"71","author":"ID Davis","year":"2017","unstructured":"Davis ID, Xie W, Pezaro C, et al. Efficacy of second-line targeted therapy for renal cell carcinoma according to change from baseline in international metastatic renal cell carcinoma database consortium prognostic category. Eur Urol. 2017;71(6):970\u20138.","journal-title":"Eur Urol"},{"issue":"3","key":"613_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11523-014-0347-4","volume":"10","author":"I Tsimafeyeu","year":"2015","unstructured":"Tsimafeyeu I, Snegovoy A, Varlamov S, et al. Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T. Target Oncol. 2015;10(3):423\u20137.","journal-title":"Target Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-018-0613-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-018-0613-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-018-0613-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T19:13:11Z","timestamp":1577992391000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-018-0613-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,3]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["613"],"URL":"https:\/\/doi.org\/10.1007\/s11523-018-0613-y","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"type":"print","value":"1776-2596"},{"type":"electronic","value":"1776-260X"}],"subject":[],"published":{"date-parts":[[2019,1,3]]},"assertion":[{"value":"3 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by a grant from the Kidney Cancer Research Bureau. No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ilya Tsimafeyeu, Pavel Borisov, Ahmed Abdelgafur, Roman Leonenkov, Olga Novikova, Irina Guseva, Marina Demchenkova, Nadezhda Mikhailova, Andrey Semenov, Zakhar Yurmazov, Irina Sivunova, Madina Ramazanova, Sergey Gamayunov, Dmitry Kosov, and Gennady Bratslavsky declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}